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ABSTRACT
Aljagthmi, Amjad Ahmed. M.S. Department of Biochemistry and Molecular Biology,
Wright State University, 2017. Np63 suppresses cell invasion by targeting Rac1
through miR-320a
ΔNp63α, a member of the p53 family of transcription factors, is overexpressed
in a number of cancers and known to play a role in proliferation, differentiation, migration
and invasion. ΔNp63α has been shown to regulate several microRNAs that play a role in
both development and cancer, but to date there has not been a global analysis of p63regulated miRNA. Using next-generation sequencing of small RNA from wild type and
sip63 transfected HaCaT cells, our laboratory recently identified a number of ΔNp63αregulated miRNAs by RNA-Seq studies which may serve as biomarkers of cancer
progression. We identified a novel miRNA, miR-320a which is positively regulated by
p63. Previous studies have shown that miR-320a is downregulated in colorectal cancer and
targets Ras-related C3 botulinum toxin substrate 1 (RAC1), leading to a decrease in noncanonical WNT signaling and EMT and thereby a corresponding decrease in tumor
metastasis and invasion. We hypothesize that ΔNp63α decreases cell invasion
through down-regulation the activity of Rac1 via miR-320a. We showed that knockdown
of ΔNp63α in HaCaT and A431 cell lines lead to a decrease in miR-320a levels and a
corresponding increase in the phosphorylation of Rac1 at Ser71, while overexpression of
ΔNp63α in SW480 and Caco2 cells led to a decrease in the S71 phosphorylation of
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Rac1. We also showed that ΔNp63α effect the GTP activity of Rac1. Knockdown of
ΔNp63α showed significant increase in Rac1 GTP levels and subsequent increase the
activity of its effector PAK1. Finally, we showed that the increase observed upon
knockdown of ΔNp63α is reversible by overexpressing miR-320a. Taken together, our data
suggest that ΔNp63α-mediated increase in miR-320a levels has potential implications for
cancer migration and metastasis.
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I.

INTRODUCTION

 Np63
ΔNp63α is a homolog of the p53 tumor suppressor gene and the dominant p63
isoform expressed in the proliferative basal layer of epithelial tissues (Mills et al., 1999;
Shimada et al., 1999; Yang et al., 1999). Like p53, p63 contains three functional domains:
a transactivation domain, a DNA binding domain (DBD), and an oligomerization domain
(Yang et al., 1998). Unlike p53, p63 exists as 6 different isoforms arising from alternative
promoter usage and differential 3’ splicing (Figure 1). The p63 gene contains two
promoters. Transcription initiation from promoter 1 (P1) yields the TAp63 isoforms that
have a full N-terminal activation domain, while initiation from promoter 2 (P2) yields the
Np63 isoforms that have a truncated N-terminal domain. The TAp63 isoforms generally
function similarly to p53, while the Np63 isoforms generally oppose p53 function
(Kommagani, Caserta, & Kadakia, 2006; Marinari et al., 2009; Ortt, Raveh, Gat, & Sinha,
2008; Osada et al., 2005; Senoo, Matsumura, & Habu, 2002). Moreover, alternative
3’splicing of TAp63 and Np63, leads to the ,  and  isoforms (Figure 
ΔNp63α is involved in many cellular processes including cellular differentiation,
proliferation, adhesion and cell survival (Mills et al., 1999; Shimada et al., 1999; Yang et
al., 1999). A previous study showed that p63 plays a crucial role in the development of
ectodermal structures during the early development stages (Mills et al., 1999). Mice lacking
p63 are born without a stratified epithelium, their limbs are truncated and they die shortly
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Figure 1: p63 isoforms. Schematic of the p63 gene comprised of the two promoter sites, 3’
splicing segments, resulting in six main p63 isoforms. The p63 domains are as follows:
transactivation domain (TA), DNA-binding (DBD), oligomerization domain (OD), sterile alpha
motif (SAM) and transactivation inhibitory domain (TI).

2

after birth due to dehydration (Mills et al., 1999; Yang et al., 1999). In addition, they lack
mammary glands, hair follicles and teeth (Mills et al., 1999).Furthermore, the loss of
Np63, but not TAp63, induces cell detachment and it has been shown that Np63
modulates many key proteins involved in cell adhesion (Carroll et al., 2006). Np63 is
the most abundantly expressed and physiologically relevant isoform of p63 (Koster, Kim,
Mills, DeMayo, & Roop, 2004).
B. Np63 and human cancer
ΔNp63α is known for its oncogenic role in squamous cell carcinoma (SCC) and
basal cell carcinoma (BCC) where it is overexpressed, and recent evidence suggests that
ΔNp63α can modulate cellular processes critical for the spread of tumors, metastasis and
epithelial-mesenchymal transition (EMT). Interestingly, invasive cancers such as
colorectal cancer (CRC) have low levels of ΔNp63α expression (Finlan & Hupp, 2007).
ΔNp63α expression is found to be decreased as cancer becomes more aggressive which
suggests that ΔNp63α can act as an oncogene in the early stages of cancer, however, it
plays a role in inhibiting cancer migration and metastasis in the late stages (Bergholz et al.,
2014; Danilov et al., 2011; Finlan & Hupp, 2007; Kommagani et al., 2009). Metastasis,
the spread of cancer cells from the site they first formed through the blood or lymph system
to other parts of the body, frequently occurs in lung, liver and brain and that serves as the
primary cause of mortality of cancer patients (Vatandoust, Price, & Karapetis, 2015). The
epithelial-mesenchymal transition (EMT) is the primary driver of tumor invasion and
migration, and is one of key cellular programs activated during cancer metastasis (Cao, Xu,
Liu, Wan, & Lai, 2015). Previous studies from ours and other laboratories have shown that
ΔNp63α dramatically inhibits cell migration and invasion, potentially by regulating
3

signaling pathways that induce the EMT (Bergholz et al., 2014; Danilov et al., 2011; Finlan
& Hupp, 2007; Kommagani et al., 2009; Leonard et al., 2011). Np63 has been shown
to inhibit EMT through miRNA-mediated regulation (Lin et al., 2015; Ratovitski, 2014;
Stacy, Craig, Sakaram, & Kadakia, 2017; Tucci et al., 2012). A number of microRNAs
(miRNAs) that are regulated by ΔNp63α have been implicated in EMT. ΔNp63α was
shown to inhibit EMT by upregulating miR-205 which suppresses Zeb1 and Zeb2
expression, EMT-related transcription factors (Chu et al., 2013; Tran et al., 2013; Tucci et
al., 2012).
C. microRNAs
microRNAs (miRNAs) are small non-coding RNA molecules of 18-24 nucleotides
in length. They regulate gene expression post-transcriptionally by binding to
complementary sequences in the 3’ untranslated region (UTR) of their target mRNA. This
binding can lead to translation inhibition or mRNA degradation (Finnegan & Pasquinelli,
2013; Kloosterman & Plasterk, 2006). miRNA synthesis begins with transcription of the
primary miRNA (pri-miRNA) by RNA polymerase II (RNA POL II) (Figure 2). The primiRNA is then processed by Drosha/DGCR8 in the nucleus to yield a hairpin structured
precursor miRNA (pre-miRNA) which is then exported to cytoplasm through Exportin 5.
The pre-miRNA is processed in cytoplasm by Dicer to produce mature double-stranded
miRNA (Figure 2). A single strand is selected from the double-stranded miRNA molecule
for loading into Argonaute (AGO) to form RNA-induced silencing complex (RISC),
whereas the second strand is degraded (Lin et al., 2015; Wahid, Shehzad, Khan, & Kim,
2010).
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Figure 2: miRNA biosynthesis. The synthesis of microRNA starts with transcribing gene into primary
miRNA (pri-miRNA) by the action of RNA Pol II. pri-miRNA is then processed by Drosha to generate
miRNA precursor (pre-miRNA) which is exported to the cytoplasm by Exportin 5. The loop region in
the pre-miRNA is removed by an endonuclease complex containing Dicer to generate a mature doublestranded miRNA. One strand of the duplex miRNAs is degraded and the other strand is loaded on
Argonaute (AGO) to form RISC which then binds to mRNA of the target gene and leads mRNA
degradation or translation inhibition.
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The miRNA-loaded RISC then binds to the target mRNA and inhibits translation or leads
to mRNA degradation (Figure 2).
A single miRNA may regulate multiple mRNAs and a single mRNA may be
targeted by multiple miRNAs, thus the dysregulation of miRNAs can have strong
consequences on the dysregulation of genes. miRNAs have been implicated in multiple
cellular processes including cell development, differentiation, proliferation and apoptosis
(Andersen, Duroux, & Gazerani, 2014). Dysregulation in miRNAs expression is greatly
involved in tumor initiation and progression, drug resistance and other cancer pathogenesis
(Ratovitski, 2014).
D. miRNA in cancer
miRNAs control the expression of proteins involved in cancer biology (Hayes,
Peruzzi, & Lawler, 2014). They can enhance or suppress the pathogenesis of cancer by
regulating the expression of tumor suppressors and oncogenes, respectively, or by directly
functioning as oncogenes or tumor suppressors (Zhang et al., 2012). Importantly, each
tumor type has a unique miRNA signature that distinguishes it from normal tissues and
other cancer types (Hayes et al., 2014). Thus, miRNAs can be used as diagnostic and
prognostic biomarkers for cancers especially since they are stable and abundant in
biological fluids such as serum, urine and saliva (Alemar, Gregorio, & Ashton-Prolla,
2015; Hayes et al., 2014).
miRNA are dysregulated in many cancers through different genetic mechanisms
such as promoter methylation, gene amplification or deletion, and regulation by
transcription factors(Hayes et al., 2014). In addition, mutations in the miRNA binding
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sites of the target mRNA is yet another mechanism observed in cancer cells which makes
mRNA insensitive (Hayes et al., 2014).
E. ΔNp63α regulation of miRNAs
Several studies showed that many proteins involved in cell death, survival, and
tumor development are controlled by Np63 through miRNA-mediated regulation (Lin
et al., 2015; Ratovitski, 2014; Stacy et al., 2017). In fact, Np63 can control miRNA
expression through regulating several steps in miRNA synthesis. It can decrease the
binding of RNA POL II to the promoter of the miRNA host gene leading to transcriptional
inhibition (Tran et al., 2013). It can also influence pri-miRNA processing through
transcriptionally regulating the expression of DGCR8 (Chakravarti et al., 2014). In
addition, p63 can control the processing of pre-miRNA by regulating the expression of
DICER (Boominathan, 2010; Huang et al., 2011). Finally, p63 can also regulate
transcription factors that control miRNA expression levels. For instance, p63 can indirectly
upregulate the expression of miR-630 and miR-885-3p by upregulating the transcription
factors CARM1, KAT2B and TFAP2A that can bind to the promoter of the of these
miRNA genes and induce their expression.
Recent studies in our laboratory sought to examine the effects of Np63 on global
miRNA regulation. Therefore small RNA sequencing studies were performed to determine
microRNAs regulation by Np63. miR-320a was identified as a novel microRNA
regulated by Np63.
F. miR-320a
miR-320a generally functions to repress tumor metastasis. Accordingly, it is
strongly downregulated in many metastatic cancer types such as Salivary adenoid cystic
7

carcinoma (SACC), colorectal cancer (CRC), non‐small cell lung cancer (NSCLC) and
breast cancer (L. Sun et al., 2015; J. Yu et al., 2016; Zhang et al., 2012; Zhao et al., 2014).
miR-320a has been shown to inhibit breast cancer metastasis in vitro and in vivo by directly
targeting metadherin (MTDH) (J. Yu et al., 2016). miR-320a also suppresses NSCLC
growth and invasiveness through downregulation of insulin‐like growth factor 1 (IGF-1)
receptor (L. Sun et al., 2015). In addition, a number of oncogenic proteins that are
upregulated in CRC are known targets for miR-320a. miR-320a inhibits colorectal cancer
growth by directly targeting SOX4, FOXM1, and FOXQ1 (Vishnubalaji et al., 2016).
Moreover, it also inhibits colorectal cancer cell migration and invasion by targeting Rac1
(Zhao et al., 2014).
G. Small GTPase-Rac1:
The Ras homology (Rho) GTPases family is subfamily of Ras small GTPases that
are small G proteins with molecular weight of ~21 kDa. The members of this family are
signaling molecules that control cellular responses to stimuli by regulating a variety of
cellular processes including actin organization, cell cycle progression, activation of protein
kinases and transcriptional regulation (Hartman & Spudich, 2012). Ras-related C3
botulinum toxin substrate 1 (Rac1) belongs to the Rho family and plays fundamental roles
in cellular proliferation, adhesion, migration and gene transcription. Rac1 is a plasma
membrane associated small GTPase encoded by RAC1 gene that also produces another
splice variant of the Rac1 protein, Rac1b (Matos & Jordan, 2006). Like other small
GTPases, Rac1 fluctuates between its active form (GTP-bound) and inactive form (GDPbound) (Figure 3). Rac1 also has GTPase activity which facilitates the hydrolysis of GTP.
This molecular switch is regulated by three types of regulatory molecules including
8

Figure 3 Rac1 molecular switch. Rac1 is a plasma membrane associated small GTPase that
cycles between its active form (GTP-bound) and inactive form (GDP-bound) by the action of
Guanine nucleotide exchange factor (GEF) and GTPase-activating protein (GAP), respectively.
GTP-Rac1 is localized to the plasma membrane, whereas GDP-Rac1 associated with Rho GDPdissociation inhibitor (RhoGDI) localized to the cytoplasm. GTP-Rac1 is also present in the
nucleus where it upregulates gene transcription.

9

Guanine nucleotide exchange factor (GEF), GTPase-activating protein (GAP) and Rho
GDP-dissociation inhibitor (RhoGDI) (Bos, Rehmann, & Wittinghofer, 2007). GEFs
activate Rac1 by facilitating the exchange of GDP with GTP, whereas GAPs facilitate the
hydrolysis of GTP to GDP and converting Rac1 to its inactive conformational state.
RhoGDI has been shown to downregulate Rac1 activity by preventing the exchange of
GDP with GTP and by sequestering Rac1 in the cytoplasm (Bos et al., 2007). Moreover,
the carboxyl (C-) terminus of Rac1 undergoes post-translation modification by prenylation
(i.e. addition of a lipid tail) that facilitates the attachment of Rac1 to plasma membrane.
RhoGDI prevents the association of Rac1 to cellular membrane and localizes it to the
cytoplasm through sequestrating this lipid tail (Figure 3) (ten Klooster, Leeuwen, Scheres,
Anthony, & Hordijk, 2007).
The subcellular localization of Rac1 is essential to its function in the cells. In
addition to its association to the plasma membrane and cytoplasm, Rac1 can also be
localized to the early endosomal compartment, the nuclear envelope and the nucleoplasm
(Navarro-Lerida et al., 2015). In fact, the subcellular compartmentalization of Rac1
depends on its activation state. When Rac1 is bound to GTP, it is detected at the plasma
membrane where it is involved in inducing the membrane ruffling and lamellipodia,
structures which are associated with cell movement and are indicative of metastasis,
through coordinating the dynamics of the actin cytoskeleton (ten Klooster et al., 2007). On
other hand, inactive GDP-Rac1 is associated with RhoGDI which is a cytoplasmic protein
and localized to the cytoplasm (ten Klooster et al., 2007).
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While the cytoplasmic and plasma membrane functions of Rac1 are well
investigated, little is known about Rac1 nuclear localization and function. Lanning et al.,
(2004) identified a molecular mechanism by which Rac1 is imported to nucleus (Lanning,
Daddona, Ruiz-Velasco, Shafer, & Williams, 2004). They found that the C-terminal
polybasic region (PBR) within Rac1 is essential to promote the interaction of Rac1 with
the nucleocytoplasmic shuttling proteins such as SmgGDs. The C-terminal poly basic
region (PBR) of Rac1 consists of a series of basic residues, lysines and arginines (Lanning
et al., 2004). The PBR contains a specific amino acid sequence called the nuclear
localization signal (NLS) that is required for shuttling Rac1 to nucleus. Other Rac isoforms,
Rac2 and Rac3, lack NLS (Sandrock, Bielek, Schradi, Schmidt, & Klugbauer, 2010). It is
thought that Rac1 nuclear importing induces its proteasome-mediated degradation. GTPRac1, but not GDP-Rac1, interacts with the anaphase-promoting complex (APC/C) that
ubiquitinates Rac1 and targets it for degradation by 26 S proteasome. Interestingly, only
Rac1 is found to be subjected to proteasomal degradation among Rac isoforms. This could
be a result of the lack of an NLS in Rac2 and Rac3. When Rac1 PBR is replaced by Rac2
PBR or Rac3 PBR, Rac1 is protected from degradation (Lanning et al., 2004).
Sequestering Rac1 to the nucleus may prevent it from interacting with cytoplasmic
proteins and inhibit its membrane ruffling induction that is driven by the assembly of actin
filaments and essential for epithelial cells to be motile (Koster et al., 2004). The fact that
Rac1 is degraded in the nucleus does not eliminate its other nuclear functions. In fact, active
nuclear Rac1 has been reported and was attributed to binding to exchange factors such as
Dock180 (Wong & Isberg, 2005). It is thought that Rac1 shuttling to nucleus occurs in a
cell cycle-dependent manner. Rac1 is not detectable in the nucleus during G1, however, it
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has been shown to accumulate in the nucleus in G2 phase. The presence of Rac1 in the
nucleus is believed to accelerate the cell cycle and protect cells from apoptosis, however,
the underlying mechanism is not understood (Michaelson et al., 2008). In addition, Rac1
participates in a number of nuclear processes that facilitate its degradation (Lanning et al.,
2004). Thus, there is a critical need for further investigation of nuclear Rac1 function(s)
and the mechanism that regulates its activation in the nucleus.
The C-terminal domain of Rac1 has been shown to bind to its downstream effectors
leading to activation of Rac1 signaling (ten Klooster et al., 2007). Active Rac1, GTP-Rac1,
can activate signaling pathways through binding to PAK (p21-activated kinase), IQ-GAP,
POSH, POR1, WASP, p67PHOX and Sra-1 (Rane & Minden, 2014). Among Rac1
effectors, p21-activated kinases (PAKs) are the best characterized and the prime mediators
of Rac1 signaling in the cells. PAKs are serine/threonine kinases that consist of 6 isoforms
(PAK1-6) and are classified into two groups based on their biochemical structures (Rane
& Minden, 2014). Group I consists of PAK1, 2 and 3, while group II consists of PAK4, 5
and 6. Both groups have an N-terminal regulatory domain and a carboxyl terminal kinase
domain, however the structure of the regulatory domains is completely different between
the two groups resulting in distinct activation mechanisms (Rane & Minden, 2014). In
addition, they share only 50% identity to Cdc42 Rac interactive binding (CRIB) domain
(Rane & Minden, 2014).
PAK1 is the most extensively studied member of PAKs and a major mediator of
Rac1 signaling. In its inactive state, PAK1 is present as homodimers in a transautoinhibitory conformation in which the autoinhibitory domain (AID) in one monomer
binds to the kinase domain in the second monomer preventing it from autophosphorylation
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(Kumar, Sanawar, Li, & Li, 2017). GTP-Rac1 binds to the CRIB domain overlapping by
the AID in PAK1 leading to disruption of the homodimerization structure, and subsequent
auto-phosphorylation of PAK1 at Ser21, Ser144 and T423 in the activation loop of the
catalytic domain in addition to other residues in other sites (Parrini, Lei, Harrison, &
Mayer, 2002; Zenke, King, Bohl, & Bokoch, 1999). Upon activation, PAK1 can
phosphorylate or interact with downstream effectors leading to regulation of a variety of
cellular processes including cytoskeleton rearrangement, survival, proliferation and cell
motility.
H. Rac1 in cancer
The dysregulation of signaling pathways regulated by Rac1 can promote various
aspects of tumorigenesis including anchorage-independent growth, cell transformation,
survival, and invasion (Navarro-Lerida et al., 2015). Rac1 expression or activity has been
shown to be frequently altered in human cancers. This alteration can be at the transcript or
protein levels of Rac1. Rac1 overexpression has been reported in multiple types of cancer
such as myeloma, head and neck squamous cell carcinomas, colorectal, pancreatic, breast,
and testicular cancers and in leukemia (Davis et al., 2013; Tong, Li, Ballermann, & Wang,
2013). Rac1 has been shown to be strongly involved in colorectal adenocarcinoma
initiation and progression (Espina et al., 2008; Matos et al., 2000). Moreover, Rac1b, a
highly activated splicing variant of Rac1 with increased expression in colorectal tumors,
was also shown to promote cell transformation and epithelial-mesenchymal transition
(Matos et al., 2000). Although, mutation in Rac1 is rarely detected, mutations in its
upstream regulators such as GEFs, GAPs or RhoGDI, or mutation in its downstream
effectors, e.g. PAK1, have been reported to alter Rac1 activity. For instance, upregulation
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of PAK1 activity is associated with the malignancy of breast cancer (Holm et al., 2006).
PAK1 also found to promote the progression of colorectal cancer (Huynh, Liu, Baldwin,
& He, 2010).
I. miRNA regulation of Rac1
Recent studies have uncovered an additional regulatory mechanism by which
miRNA can alter Rac1 expression and activity. For example, miR-320a suppresses
colorectal cancer progression by directly binding to the 3’-UTR of Rac1 and
downregulating its protein levels (Zhao et al., 2014). Moreover, miR-124 is reported to
negatively regulate Rac1 by changing its localization to nucleus, without affecting its
protein levels, where it participates in signaling pathways that target its degradation
(Figure 3) (Lanning et al., 2004; J. Y. Yu, Chung, Deo, Thompson, & Turner, 2008).
miRNA can also indirectly regulate Rac1 activity through targeting GEFs or GAPs
upstream of Rac1. miR-512-3p is found to inhibit migration and invasion in non-small cell
lung cancer (NSCLC) through down regulating Rac1-GEF, DOCK3 (Zhu et al., 2015).
Taken together, these studies demonstrate both direct and indirect regulation of Rac1
signaling by miRNA.
J. Phosphorylation of Rac1
The function of Rac1 may also be modulated via protein phosphorylation. Rac1 has
been shown to be phosphorylated at multiple sites (Table 1).

Although the

phosphorylation of other Rho family members RhoA and CDC42 limits their functions and
increases their binding to RhoGDI, the effect of Rac1 phosphorylation on its activity is not
fully understood (Forget, Desrosiers, Gingras, & Beliveau, 2002). ERK1/2 directly
interacts with Rac1 through an ERK D site that is present in the C-terminus of Rac1. This
14

interaction results in phosphorylation of Rac1 at T108 by ERK1/2 (Tong et al., 2013). Rac1
phosphorylated at T108 showed less binding to PAK and accumulated in the nucleus. It is
suggested that this accumulation isolates Rac1 from the cytoplasmic GEFs that are not
localized to nucleus. However, phospho-Rac1 T108 is still able to interact with other
molecules in the nucleus and regulates different cellular process. Thus, phosphorylation
of Rac1 at T108 may inhibit the migratory function of Rac1 by isolating it to nucleus,
however, it retains its activity in terms of cell growth and proliferation.
Y64 in Rac1 is shown to be phosphorylated by Focal Adhesion Kinase (FAK) and
Src kinase (Table1). The phosphorylation at this site inhibits cell spreading and decreases
Rac1 binding to PAK. It also increases the binding of Rac1 to RhoGDI (Chang, Lemmon,
Lietha, Eck, & Romer, 2011). Thus, phosphorylation of Rac1 at Y64 is thought to decrease
its activity. By contrast, FAK has been reported before to upregulate Rac1 activity by
phosphorylating PIX (PAK-interacting exchange factor) and increasing its binding to
Rac1. PIX targets Rac1 to focal adhesion and leading to an upregulation in cell spreading
and migration (Chang et al., 2011).
AKT can phosphorylate Rac1 at S71 (Table 1). Phosphorylation at S71 decreases
Rac1 binding to GTP since this phosphorylation site is located in Switch II domain (Rac1
residues 57–75), where the GTP can bind (Kwon, Kwon, Chun, Kim, & Kang, 2000;
Worthylake, Rossman, & Sondek, 2000). Another study showed that Rac1 phosphorylation
does not affect the activity of Rac1, but rather leads to a decrease in Rac1 binding to
specific effectors and a shift in specificity toward other effectors (Schwarz et al., 2012) .
Another study showed that phosphorylation of Rac1 interferes with its interaction with
RhoGDI, while pRac1 still binds to PAK1 even though the phosphorylation decreases
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Table1: Known phosphorylated residues in Rac1
Rac1 residue

Kinase

References

T108

ERK1/2

(Tong et al., 2013)

Y64

Src

(Chang et al., 2011)

Y64

FAK

(Chang et al., 2011)

S71

Akt

(Kwon et al., 2000)
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its GTP binding (Schoentaube, Olling, Tatge, Just, & Gerhard, 2009). Thus, the impact of
S71 phosphorylation on Rac1 activity and function is controversial and poorly understood
and more investigation is needed.
Rac1 phosphorylation at T108, Y64 and S71 occurs in an EGF-dependent manner.
Rac1, but not CDC42 or RhoA, has been shown to be required for EGF-stimulated
migration (Dise, Frey, Whitehead, & Polk, 2008). EGF stimulates SRC and PI3K resulting
in an upregulation of Rac1 activity (Dise et al., 2008). Phosphorylation of related GEFs
has not been identified. These two kinases work in parallel to activate Rac1 and the
inhibition of one of them does not block the activity of the other (Dise et al., 2008).
K. Significance
Determining the mechanisms by which p63 regulates migration and invasion
is critical for understanding its proto-oncogenic functions and thereby the appropriate
conditions for its use as chemotherapeutic agent. Previous studies and our data indicate that
Np63 plays an important role in inhibiting invasion and migration. Np63 is known
for its pro-proliferative oncogenic role in Squamous cell carcinoma (SCC) and basal cell
carcinoma (BCC) where it is overexpressed (Bircan, Candir, Kapucoglu, & Baspinar, 2006;
Lo Muzio et al., 2005; Reis-Filho, Torio, Albergaria, & Schmitt, 2002). The mechanisms
by which Np63 negatively regulates tumor invasion and migration are not fully
understood. Based on previous studies and our data, we hypothesize that ΔNp63α
positively regulates miR-320a resulting in reduced migration and invasion through
modulation of Rac1 activities. The proposed study will advance our understanding of the
role played by Np63 in regulating EMT and thereby cancer progression. Our goal is to
elucidate the mechanisms by which ΔNp63α inhibits invasion and metastasis, and to
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determine if ΔNp63α elicits these functions through its regulation of miR-320/Rac1. Our
purposed studies will fill a gap in understanding of ΔNp63α-mediated inhibition of cancer
migration and invasion.
L. Rationale
ΔNp63α expression is downregulated in a number of invasive cancers (Finlan &
Hupp, 2007). EMT represents one of cellular programs that are activated during cancer
metastasis and can drive tumor invasion and migration. Multiple markers associated with
EMT are shown to be affected by ΔNp63α (Olsen et al., 2013; Stacy et al., 2017; Tran et
al., 2013). ΔNp63α can act as an oncogene in the early stages of cancer, however, it plays
a role in inhibiting cancer migration and metastasis in the late stages (Bergholz et al., 2014;
Danilov et al., 2011; Finlan & Hupp, 2007; Kommagani et al., 2009). Previous studies and
data from our laboratory showed that ΔNp63α inhibits cell migration and invasion,
potentially by inhibiting signaling pathways that induce EMT (Bergholz et al., 2014;
Danilov et al., 2011; Finlan & Hupp, 2007; Kommagani et al., 2009; Leonard et al., 2011).
miR-320a is downregulated in many cancer types such as colorectal cancer (CRC)
and non‐small cell lung cancer (NSCLC). Small RNA sequencing studies from our
laboratory indicated that mi-R320a is positively regulated by Np63. miR-320a is known
to downregulate a number of oncogenic proteins such as SOX4, FOXM1 and Rac1 that are
involved in EMT (Vishnubalaji et al., 2016; Zhao et al., 2014). Chief among these is Rac1,
a key protein that modulates actin cytoskeletal dynamics including cell adhesion and
motility (Zhao et al., 2014). Rac1 activity is upregulated in several different tumor types
and correlate with aggressive malignant characteristics (Bid, Roberts, Manchanda, &
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Houghton, 2013). Our preliminary data showed that Np63 negatively regulates Rac1
activity and changes its subcellular localization to nucleus, thus, suggesting a potential
mechanistic link between p63 and cancer invasiveness through the regulation of Rac1.
Therefore, in this study we tested whether Np63 could potentially inhibit the activities
of Rac1 through upregulating miR-320a levels.
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II.

II. MATERIALS AND METHODS

A. Cell culture and Reagents
The squamous cell carcinoma cell line A431, the human non-small cell lung
carcinoma H1299, the colorectal adenocarcinoma SW480 and the colorectal
adenocarcinoma Caco2 were purchased from American Type Culture Collection
(Manassas, Virginia, USA). The non-tumorigenic immortalized human keratinocyte
HaCaT cell line was obtained from Dr. Nancy Bigley (Wright State University). The five
cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 8 % fetal bovine serum (FBS) and 250 U penicillin and 250 g streptomycin.
B. microRNA and siRNA transfection
miR-320a mimic and miRNA mimic negative control were obtained from
Dharmacon (Lafayette, CO, USA). The mature sequence for miR-320a mimic is 5’AAAAGCUGGGUUGAGAGGGCGA-3’ and the mature sequence for miRNA mimic
negative control is 5’-UCACAACCUCCUAGAAAGAGUAGA-3’. A total of 40 nM of
miR320a mimic or mimic negative control was transfected into A431 or HaCaT cells using
Lipofectamine RNAi-Max as per manufacturer’s instructions (Life Technologies,
Carlsband, CA, USA). miR-320a inhibitor and miRNA inhibitor negative control were
also obtained from Dharmacon (Lafayette, CO, USA). The precursor sequence for miR320a inhibitor is 5’-GCUUCGCUCCCCUCCGCCUUCUCUUCCCGGUUCUUCCCGG
AGUCGGGAAAAGCUGGGUUGAGAGGGCGAAAAAGGAUGAGGU-3’ and the
mature

sequence

for

miRNA

inhibitor
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negative

control

is

5’-

UCACAACCUCCUAGAAAGAGUAGA-3’. A total of 40 nM of miR-320a inhibitor or
inhibitor negative control was transfected into A431 using Lipofectamine RNAi-Max.
Rac1 and p63 knockdown studies conducted in HaCaT and A431 cells were performed by
two rounds of siRNA transfection using Lipofectamine RNAi-Max. Rac1 and p63 siRNA
used in this study were purchased from Qiagen (Valencia, CA, USA). A pool of four
siRNAs was used to target Rac1: 5’-ATGCATTTCCTGGAGAATATA-3’, 5’CAGCACGTGTTCCCGACATAA-3’, 5’-ACGAAGTGGAGATTTACACTA-3’ and 5’ACAAGCCTTCTTAAAGCCTTA -3’, and the siRNA sequence used for p63 was 5’CACCCTTATAGTCTAAGACTA-3’.
C. DNA constructs and transient transfections
EGFP-tagged wild type Rac1, dominant-negative Rac1 (T17N) and constitutive
active Rac1 (Q61L) constructs were purchased from Addgene (Cambridge, MA, USA).
EGFP-tagged Rac1 S71A was generated commercially by site-directed mutagenesis
(GenScript, Piscataway, NJ), and the mutant sequence was verified by sequencing the
entire coding region. Np63, Rac1-WT, T17N Rac1, Q61L Rac1 or S71A Rac1
expression vectors or the empty vector control, pcDNA3.1, was transiently transfected into
H1299, SW480 or Caco2 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). Briefly, cells were trypsinized and plated onto a six-well plate at a density of
3.0 × 105 cells / well for H1299 and 5.0× 105 cells / well for SW480 and Caco2 cells per
well in 2 ml of DMEM plus 8% FBS with 250 U penicillin and 250 g streptomycin for
24 hours. 1μg of plasmid DNA in 250 μl of Opti-MEM (Invitrogen, Carlsbad, CA, USA)
was mixed with 2 μl of Lipofectamine 2000 in 250 μl of Opti-MEM, incubated for 20
minutes and added to cells in DMEM media supplemented with 8% FBS without antibiotic
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for overnight incubation. The following day, media was changed to DMEM plus 8% FBS
with 250 U penicillin and 250 g streptomycin. Cells were harvested 24 hours after
transfection and cell pellets were used for immunoblot analysis and extraction of total RNA
for qRT-PCR studies.
D. Immunoblot analysis
Whole cell lysates were prepared by lysing cells in phosphatase inhibitors
containing buffer (50mM Tris-HCl pH 8, 120 mM NaCl, 5mM sodium pyrophosphate
phosphatase inhibitor [NaPPi], 10mM NaF, 30 mM paranitrophenylphosphate, 1mM
benzamidine, 0.1% NP-40, 1% Triton X-100 and 0.2 PMSF, 100nM sodium
orthovanadate) supplemented with 10% protease inhibitor cocktail (Sigma, St. Louis, MO).
Total protein concentrations were determined by BCA assay (Thermo Fisher Scientific
Inc., Fremont, CA, USA). Equivalent concentrations of protein were resolved on 10%
SDS-PAGE and transferred to polyvinylidene difluoride membranes. Proteins were
detected using rabbit polyclonal anti-GFP (FL) and mouse monoclonal anti β-actin
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) used at 1:1,000 and
1:10,000, respectively. β-actin was used as a loading control. Rabbit polyclonal anti-p63
[N2C1] (Gene Tex, Irvine, CA, USA). Mouse monoclonal anti-Rac1 (Abcam, Cambridge,
MA, USA) was used at 1:1,000 to 1:2,000. Rabbit polyclonal anti-Rac1 (C-11) and rabbit
polyclonal anti-phospho-Rac1 (Ser71) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
were used at1:500 and 1:1,000, respectively. Rabbit polyclonal anti-PAK1 and rabbit
polyclonal anti-pPAK1/2 (Cell Signaling Biotechnology, Cambridge, MA, USA) were
used at 1:500. Appropriate horseradish peroxidase-conjugated secondary antibodies
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(Promega, Madison, WI, USA) were used for chemiluminescence detection with Western
Lightning Plus chemiluminescent kit (Perkin Elmer, Waltham, MA, USA).
E. Rac1 activation assay
A Rac1 pull-down activation assay (Cytoskeleton, BK035, Denver, CO) was used
to measure Rac1-GTP activity. Whole cell lysates were prepared by lysing cells in ice-cold
lysis buffer (50mM Tris pH 7.5, 10mM MgCL2, 0.5M NaCL, and 2% Igepal) containing
1X Protease Inhibitor Cocktail and protein concentrations were determined by BCA assay
(Thermo Fisher Scientific Inc., Fremont, CA, USA). Equivalent concentrations of protein
(500 g) were added to 10 μl of p21-activated kinase-protein binding domain (PAK-PBD)
beads and rotated at 4°C on a tube rotator for 1 hour. Next, the PAK-PBD beads were
pelleted by centrifugation at 5,000 x g at 4°C for 1 minute. After removing about 90 % of
the supernatant, the pellet was washed one time with 500 μl of wash buffer. GTP-Rac1
bound to PAK-RBD beads were run on an SDS-PAGE (10% gradient gel),
electrotransferred to a polyvinylidene difluoride membrane (Sequi-Blot PVDF
membranes; BIO-RAD). After blocking with 5 % milk, membranes were probed with a
rabbit polyclonal anti-Rac1 (C-11) to detect total Rac1 and rabbit polyclonal anti-phosphoRac1 (Ser71). Subsequently, the membranes were probed with a mouse monoclonal antiRac1 (Abcam) which detects both pRac1 and total Rac1. Antibodies dilutions used as
described previously in section D.
F. Cell Immunofluorescence Assay
H1299 cells were grown on sterile glass coverslips and transiently transfected with
the following plasmids: GFP-Rac1 WT, GFP-Rac1 S71A, GFP-Rac1 T17N and GFP-Rac1
Q61L alone or along with overexpression of Np63. At 24 hours post transfection, cells
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were fixed with 2% paraformaldehyde for 15 min. After three consecutive washes with
PBS, cells were permeabilized with 0.2% Triton X-100 diluted in PBS for 5 min. Cells
were washed and blocked with 0.5% normal goat serum in PBS (PBS-NGS) three times 5
min each before incubating with rabbit polyclonal anti-p63 (H129) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) primary antibody used at 1:100 dilution for 1 h at
room temperature. Excess primary antibody was removed with three consecutive 5 min
washes in PBS-NGS followed by incubation with AlexaFluor goat anti-rabbit 568 used at
1:500 for 1 h at room temperature. Excess secondary was removed with three consecutive
5 min washes in PBS-NGS and one wash in PBS prior to mounting with Vecta-Shield plus
DAPI Mounting Media (Vector Laboratories, Burlingame, CA, USA). Cells were
visualized and captured with a Leica CTR 6000 Microscope (Leica Microsystems, Wetzlar,
Germany) using a 63X objective and analyzed using ImagePro 6.2 software (Media
Cybernetics, Bethesda, MD). Rac1 subcellular localization was quantified by imaging at
least 100 cells per condition with the same exposure parameters. The localization of Rac1
in plasma membrane, cytoplasm or nucleus was determined manually by evaluating each
single cell.
G. Migration and Invasion assay
Cell migration and invasion was assessed using a two-chamber transwell system.
For migration assays, a total of 9 x 104 stable transfected SW480 cells, 8 x 104 transient
transfected A431 or HaCaT cells were suspended in 200 l of serum-free DMEM medium
and seeded into 8 m pore size inserts (BD Biosciences) and placed into 24-well plate.
Then, 600 l of DMEM containing 8% FBS was added to the bottom of each insert. Cells
were incubated at 37 °C and allowed to migrate for 18 hours for SW480 and 21 hours for
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A431 and HaCaT cells following. Cells that did not migrate were removed with cotton
swab and migrated cells which had attached to the bottom of the transwell were fixed with
4% of paraformaldehyde for 20 min and washed once with Dulbeco’s Phosphate Buffered
Saline . Next, cells were stained with 600 l of crystal violet solution (0.1g in 100 ml of
H2O) for 10 min and then washed with water. Cells were visualized and imaged in four to
six random fields at magnification of 40X using a Leica CTR 6000 Microscope (Leica
Microsystems, Wetzlar, Germany) and ImagePro 6.2 software (Media Cybernetics,
Bethesda, MD). Cells were counted manually from these pictures and average was taken
to calculate the standard deviation. Invasion assay was performed using the same protocol
except that transwell inserts were coated with 1 mg/ml Matrigel (BD Biosciences) to
measure cell invasion. A total of 1.4 x 105 stable transfected SW480 cells were suspended
in 200 l of serum-free DMEM medium and seeded into 8 m pore size inserts and allowed
to invade for 21 hours at 37 °C.
H. Quantitative Reverse transcription PCR for gene expression
mRNA expression: Total RNA was extracted from human cell lines using the EZNA
RNA isolation kit according to the manufacturer protocol (Omega Bio-Tek, Norcross, GA,
USA). A TaqMan reverse transcription kit (Life Technologies, Carlsbad, CA USA) was
used to synthesize cDNA from 1g of total RNA. Quantitative real-time PCR was
performed using the Applied Biosystem 7900HT or QuantStudio 7 Flex Real-Time PCR
Systems using using Assay on Demand (AOD) specific for the genes of interest and
normalized to endogenous GAPDH for human genes (Life Technologies, Carlsbad City,
CA, USA) (Kommagani et al., 2009; Pfaffl, 2001). AODs used were GAPDH (4325792),
RAC1 (Hs01902432_s1) and pan-p63 (Hs00978340_ml).
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miRNA expression- Total RNA was extracted from human cells using the EZNA
RNA isolation kit according to the manufacturer protocol (Omega Bio-Tek, Norcross, GA,
USA). TaqMan MiroRNA reverse transcription kit (Life Technologies, Carlsband, CA,
USA) was used to synthesize cDNA from 10 ng of total RNA with primers specific to hsamiR-320a (RT:002277) or RNU-48 (RT:001006) as per manufacturer protocol.
Quantitative real-time PCR was performed using the Applied Biosystem 7900HT or
QuantStudio 7 Flex Real-Time PCR Systems using TaqMan 2X universal master mix and
miRNA specific assays on demand. Assays on demand used were hsa-miR-320a
(TM:002277) normalized to RNU-48 (TM:001006). qRT-PCR was done in triplicate for
each specific gene of interest for each sample.
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III.

RESULTS

A. Np63 positively regulates miR-320a
EMT, a process in which epithelial cells lose their characteristics and gain a
mesenchymal-like phenotype, is a fundamental process in embryonic development and
during wound healing (Kalluri & Weinberg, 2009). In carcinogenic context, EMT is
upregulated which allows cancer cells to lose their cell-cell adhesion and gain migratory
and invasive properties. Np63 plays an important role in inhibiting EMT by
upregulating genes involved in cell adhesion, while loss of Np63 upregulates genes that
promote cell motility and mesenchymal phenotypes (Tucci et al., 2012; Yoh et al., 2016).
Np63 is a known regulator of miRNA, including many which have been shown to
regulate EMT (Tran et al., 2013; Tucci et al., 2012). Thus, small RNA sequencing was
performed by Dr. Natasha Hill and Suraj Sakaram to study the regulation of miRNA by
Np63. Np63 was silenced in three biological replicates of HaCaTs, a nontumorigenic keratinocyte cells which express Np63. Np63 protein and transcript
levels were significantly reduced by 80% in cells transfected with siRNA specific to p63
relative to non-silencing (NSC) controls (Figure 4A) (representative data shown).
Following confirmation of p63 knockdown by immunoblot and qRT-PCR analysis, small
RNA was sequenced using the Ion Torrent Platform. Differential gene expression analysis
was performed using Partek Flow and PGS which led to the identification of several
miRNAs potentially regulated by the knockdown of Np63Table 2 represents a subset
of7 microRNAs significantly regulated by Np63 Of these, let-7d-5p was previously
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Figure 4: Np63knockdown in HaCaT cells leads to a reduction in miR-320a
levels. (A) HaCaT cells were transfected with non-silencing control siRNA and
siRNA against p63. At 24 h post-transfection, the change in transcript levels of
Np63 was measured by Taqman based qRT-PCR. In the bottom panel,
immunoblot analysis was performed with the indicated antibodies. Immunoblot
with -actin was performed to confirm equivalent protein loading. (B) miR-320a
transcript levels in NSC and sip63 HaCaT samples following small RNA sequencing
on HaCaT cells transfected with the indicated siRNA. Error bars indicate +1
standard deviation.
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miRNA

p-Value

Fold Change

hsa-let-7d-5p*

8.68x10-231

-1.68

hsa-miR-141-3p+

2.42x10-14

-1.19

hsa-miR-23a-3p+

2.09x10-132

-1.19

hsa-miR-24-3p+

9.33x10-24

-1.31

hsa-miR-31-5p+

7.77x10-263

-1.38

hsa-miR-320a+

3.92x10-87

-1.42

hsa-miR-9-5p+

5.79x10-18

1.45

Table 2: Knockdown of p63 identified putative p63-regulated miRNAs involved in
EMT. Small RNA was isolated from three biological replicates of HaCaT cells
transfected with non-silencing control or p63 siRNA and sequenced on the IonTorrent
platform. Partek Flow was used to identify miRNA with significant changes in
expression (p≤0.05) and to identify differentially expressed miRNA with known roles
in EMT. * indicate known p63 Targets; + indicate novel p63 targets.
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shown to be regulated by Np63(Boominathan, 2010), and the remaining 6 were novel
miRNAs. In this study we only focused on miR-320a. miR-320a is a metastatic repressor
that is known to inhibit EMT via targeting Wnt pathway and which has not previously
shown to be regulated by p63 (J. Y. Sun et al., 2012; Zhao et al., 2014). Np63
knockdown led to a concomitant decrease in miR-320a levels (Fold Change = -1.42, p =
3.92x10-87) (Table 2, Figure 4 B). Therefore miR-320a is positively regulated by Np63.
In order to validate miR-320a is positively regulated by Np63, we silenced
Np63 in HaCaT cells, the same cell line used in the RNA sequencing study which
identified miR-320a as a putative p63-regulated miRNA. Np63 was also silenced in
A431 squamous cell carcinoma cells that have Np63 as the only expressed form of p63
(Kommagani et al., 2009). HaCaT and A431 cells were transfected with siRNA against
Np63 resulting in a greater than 80% reduction in Np63 transcript in both cell lines
and no detectable p63 protein in sip63 whole cell lysates by immunoblotting, thus p63
knockdown (Figure 5A). Knockdown of Np63 led to a significant reduction in miR320a transcript levels in A431 (FC= 0.47 ± 0.04) and in HaCaT (FC= 0.69 ± 0.05) cell
lines (Figure 5B), thus validating the NGS data (Table 2).
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Figure 5: Np63 knockdown leads to a reduction in miR-320a transcript levels.
(A) A431 and HaCaT cells were transfected with nonsilencing control siRNA (NSC) or
siRNA specific to p63. The change in mRNA level and protein expression of Np63
were measured by Taqman based qRT-PCR and immunoblot analysis. Immunoblot with
-actin was performed to confirm equivalent protein loading. (B) Taqman based qRTPCR was used to quantify miR-320a levels from the experiment described in (A). Error
bars indicate +1 standard deviation. Significant changes with p ≤ 0.05 are indicated with
an asterisk.
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To further verify that Np63 regulates miR-320a, we examined the effects of
Np63 overexpression on miR-320a in SW480, a colorectal adenocarcinoma cell line,
and H1299, a human non-small cell lung carcinoma cell line. Both of these cell lines are
highly invasive and do not express Np63. H1299 and SW480 cells were transfected with
a plasmid encoding Np63or the corresponding empty plasmid vector (EV) as a control.
At 24 hours post-transfection, p63 transcript and protein levels were examined by qRTPCR and immunoblotting, respectively. As shown in Figure 6A we observed a significant
increase in both p63 transcript and protein levels confirming Np63 overexpression in
both cell lines. Endogenous Np63 was not detected in cells transfected with EV for
either cell line, while robust overexpression was shown in cells transfected with Np63
plasmids (Figure 6A, bottom). miRNA qRT-PCR quantitation of miR-320a levels in
these cells indicated that miR-320a was upregulated in cells overexpressing Np63
compared to cells transfected with EV. miR-320a transcript levels increased significantly
in both H1299 (FC= 1.68 ±0.27) and in SW480 (FC= 1.3 ±0.16) (p≤0.05) (Figure 6B).
Taken together, these results along with the knockdown experiments confirm that Np63
positively regulates miR-320a.

32

Figure 6: Np63 overexpression leads to an increase in miR-320a transcript
levels. (A) H1299 and SW480 cells were transfected with empty vector (EV) control or
expression plasmid encoding Np63. Transcripts were quantified by qRT-PCR (upper
panel) while protein levels were confirmed using immunoblot analyses (lower panel).
Immunoblot with β-actin was performed to confirm equivalent protein loading. (B)
Taqman based qRT-PCR was used to quantify miR-320a levels from the experiment
described in (A). Error bars indicate +1 standard deviation. Significant changes with p
≤ 0.05 are indicated with an asterisk.
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B. Np63 does not regulate the total protein levels of Rac1
miR-320a exerts its metastatic suppressive function through targeting genes
involved in EMT (J. Y. Sun et al., 2012; Zhao et al., 2014). Using TargetScan 7.1 and
miRDB.org, Rac1 was identified as a putative target for miR-320a. In addition, a previous
study showed that miR-320a suppresses EMT in colorectal cancer through targeting Rac1
(Zhao et al., 2014). Since we validated that Np63 positively regulates miR-320a, we
next sought to determine if regulation of Rac1 by Np63could be detected in H1299 and
SW480 cells. We overexpressed Np63 in H1299 and SW480 cells and measured the
change in Rac1 transcript and protein levels. Np63 overexpression in H1299 and
SW480 cells was confirmed by immunoblotting with p63 specific antibody (Figure 7A).
Np63 overexpression did not significantly affect the transcript levels of Rac1 in H1299
(FC= 1.14 ± 0.18) and in SW480 (FC= 0.90 ±0.04) cells (Figure 7A upper). Furthermore,
no change in total protein levels in Rac1 was observed in both those cell lines (Figure 7A
bottom). Conversely, we silenced Np63 in HaCaT and A431 cells. The loss of Np63
protein was confirmed by immunoblot (Figure 7B). Although Np63 knockdown led to
a modest increase in Rac1 transcript levels in A431 (FC= 1.31 ±0.11) and HaCaT (FC=
1.41 ±0.20), there was no change in total protein levels of Rac1 (Figure 7B). These data
suggest that Np63 does not regulate Rac1 protein and transcript levels and Rac1 in our
studies is not affected by miR-320a levels.
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*

Figure 7: Np63 does not regulate the Rac1 protein levels. (A) H1299 and SW480
cells were transfected with empty vector (EV) control or expression plasmid encoding
Np63. Np63 transcript levels were quantified by qRT-PCR while protein levels
were confirmed using immunoblot analyses using p63 specific antibody. Rac1 was
detected with mouse anti-Rac1 antibody from Abcam. (B) A431 and HaCaT cells were
transfected with nonsilencing control siRNA (NSC) or siRNA specific to p63. The
change in transcript and protein levels of Rac1 were measured by TaqMan based qRTPCR and immunoblot analysis, respectively. Immunoblot with β-actin was performed
to confirm equivalent protein loading. Error bars indicate +1 standard deviation.
Significant changes with p ≤ 0.05 are indicated with an asterisk.
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C. Np63 negatively regulates phospho-Rac1 at S71
Interestingly, the mouse monoclonal anti-Rac1 antibody obtained from Abcam that
we used to probe for Rac1 protein levels detects two bands close to the expected 21kDa
molecular weight of Rac1. Although we did not see change in the band that appeared at 21
kDa which was assumed to be total Rac1, the higher 26 kDa band showed a significant
increase with the knockdown of Np63 (Figure 8A) and a significant decrease with the
overexpression of Np63 (Figure 8B). Interestingly, this observation happened in every
experiment and in all cell lines except H1299 cells (Figure 8A). Rac2 and Rac3 isoforms
have the same molecular weight of Rac1, thus eliminating the possibility that the upper
band could be either of these Rac isoforms. Rather, it appeared likely that the 26 kDa band
observed might be phosphorylated Rac1 as phospho-Rac1 at S71 was is detected at 26 kDa
. To determine if the upper band was indeed phosphorylated Rac1, we obtained two other
Rac1 antibodies: rabbit polyclonal anti-Rac1 (C-11) that detects total Rac1 and rabbit
polyclonal anti-phospho-pRac1 which detects phospho-Rac1 at Ser 71 (Table 3). We
overexpressed Np63 in two colorectal adenocarcinoma cell lines, SW480 and Caco2,
and confirmed overexpression of Np63 at the protein levels in both cell lines (Figure
9A). Using the phosphospecific antibody for pRac1 S71, a single band was detected at 26
kDa which showed a significant decrease in cells overexpressing Np63 (Figure 9A).
Anti-Rac1 C-11 antibody was used to detect total Rac1 that was observed at 21 kDa. To
further confirm these findings, we also knocked down Np63 in A431 and HaCaT and
we observed that pRac1 S71 significantly increased with Np63 silencing (Figure 9B).
Thus, these findings suggest that the band at 26 kDa detected earlier using the Abcam
mouse monoclonal anti-Rac1 antibody was pRac1, and further that Np63
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Figure 8: Np63 negatively regulates an p-Rac1 reactive 26 kDa protein. (A)
H1299 and SW480 cells were transfected with empty vector control or expression
plasmid encoding Np63 Overexpression of Np63 was confirmed using
immunoblot analyses. (B) A431 and HaCaT cells were transfected with nonsilencing
control siRNA (NSC) or siRNA specific to p63. The change in Np63 and Rac1
protein levels were measured by immunoblot analysis as indicated. Immunoblot with βactin was performed to confirm equivalent protein loading.

37

Table 3: Rac1 antibodies used to detect protein levels of Rac1.
Antibody

Bands detected

Mouse monoclonal anti-Rac1Abcam
Rabbit polyclonal antiphospho-Rac1 (Ser71)-Santa
Cruz
Rabbit polyclonal anti-Rac1
(C-11) -Santa Cruz

Detects total Rac1: unphosphorylated and
phosphorylated Rac1
Detects only pRac1 at S71

Detects only unphosphorylated Rac1
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Figure 9:Np63 negatively regulates Rac1 S71 phosphorylation. (A) SW480 and
Caco2 cells were transfected with empty vector control or expression plasmid encoding
Np63 protein levels were confirmed using immunoblot analyses. (B) A431 and
HaCaT cells were transfected with nonsilencing control siRNA (NSC) or siRNA
specific to p63 and the change in protein expression was measured by immunoblot
analysis. Immunoblot with β-actin was performed to confirm equivalent protein
loading.
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negatively regulates phosphorylation of Rac1 at S71, but not total Rac1 levels. However,
further investigation was needed to confirm the specificity of the pRac1 antibody.
D. Phospho-Rac1 antibody is specific
Until recently, there was no antibody available that could detect the
phosphorylation of Rac1 at S71. Previous studies that investigated the phosphorylation of
Rac1 used antibodies that could not distinguish between pRac1 and pCdc42 S71 and were
therefore limited to use in cells lacking Rac1 gene (Kwon et al., 2000; Schoentaube et al.,
2009; Schwarz et al., 2012). To confirm that the phosphospecific antibody was specific for
pRac1 S71, we silenced either Np63 alone, Rac1 alone, or both Np63 and Rac1 in
HaCaT cells. Immunoblot analysis confirmed the successful knockdown of Np63 and
Rac1 in these cells (Figure 10, lanes 2 and 3 respectively). The rabbit polyclonal antiRac1 C-11 antibody was used here to confirm the silencing of Rac1. As expected, the 26
kDa band increased significantly with the silencing of Np63 alone and disappeared
when Rac1 was silenced (Figure 10, compare lanes 2 and 3 to lane 1). Interestingly when
both Np63 and Rac1 were silenced, the 26 kDa band was not observed (Figure 10, lane
4), thus confirming that anti-phospho-Rac1 antibody is specific and detects phosphorylated
Rac1. Taken together, this experiment confirm phospho-Rac1 antibody specificity and
indicate that the lower 21 kDa band is total Rac1 and the upper 26 kDa band is pRac1
Ser71.

40

Figure 10: The Santa Cruz anti-pRac1 (S71) antibody is specific for pRac1 S71.
HaCaT cells were transfected with nonsilencing control siRNA (NSC), siRNA specific
to p63 and/or Rac1 as indicated. The change in protein expression was measured by
immunoblot analysis using p63, Rac1 and pRac1 antibodies as indicated. Immunoblot
with β-actin specific antibody was performed to confirm equivalent protein loading.
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E. Np63 negatively regulates pRac1 S71 via miR-320a
Since we showed that Np63 positively regulates miR-320a and negatively
regulates pRac1 S71, we next wanted to investigate if Np63 negative regulates pRac1
S71 via upregulating miR-320a. We used miRNA gain or loss of function experiments
using a miR-320a mimic that functions like endogenous miR-320a or a single-stranded
miR-320a inhibitor designed to bind to and inhibit endogenous miR-320a. Both HaCaT
and A431 cells were co-transfected with siRNA against p63 or NSC along with negative
control mimic or miR-320a mimic. HaCaT cells have endogenous Np63that suppresses
pRac1S71 levels; thus, pRac1 S71 was detected at the basal levels when NSC and negative
control mimic were co-transfected (Figure 11A). Silencing Np63 upregulated the levels
of pRac1 S71 as observed early (Figure 11A, lane 2). Overexpressing miR-320a
significantly decreased pRac1 to the basal levels when Np63was silenced in both
HaCaT cells (Figure 11A, lane 4) and A431 cells (Figure 11B). These results clearly
demonstrate that miR-320a rescued the effect of Np63 silencing on pRac1 S71 protein
levels
Next we wanted to examine the effect of miR-320a inhibitor on pRac1 levels in presence
or absence of Np63. A431 cells with endogenous Np63 were transfected with
negative control inhibitor or miR-320a inhibitor. The miR-320a inhibitor significantly
increased pRac1 S71 levels in the presence of endogenous Np63 (Figure 12). Together,
these results demonstrate that Np63 negatively regulates the levels of pRac1 through
upregulation of miR-320a. It is likely that miR-320a may target an upstream regulator that
induces the phosphorylation of Rac1.
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Figure 11: Overexpression of a miR-320a mimic counters the effect of Np63
knockdown on Rac1 phosphorylation. HaCaT (A) and A431 (B) cells were transfected
with either non-silencing control (NSC) or siRNA specific for p63 in conjunction with a
negative control mimic or miR-320a mimic. The change in indicated protein levels were
measured analyzed via immunoblotting with p63, Rac1 and pRac1 antibodies as indicated.
Immunoblot with β-actin was performed to confirm equivalent protein loading.
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Figure 12: Inhibition of miR-320a increases pRac1 S71 levels. A431 cells were
transfected with a negative control inhibitor or miR-320a inhibitor. The change in
protein levels were analyzed via immunoblot as indicated. Immunoblot with β-actin was
performed to confirm equivalent protein loading.
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F. Np63 negatively regulates GTP-Rac1 levels
Rac1 is considered in its active state when it is bound to GTP. GTP-bound Rac1
has been shown to control cell shape, adhesion and mobility (Hartman & Spudich, 2012).
It is shown that the phosphorylation of Rho small GTPases inhibits their activity by
increasing their interaction with RhoGDI (Forget et al., 2002). However, there are multiple
contradicting reports about the effect of phosphorylation on Rac1 activity. Phosphorylation
of Rac1 at S71 by AKT kinase was shown to inhibit its GTP-binding activity (Table 1)
(Kwon et al., 2000). However, pRac1 S71 was also shown to bind to the PAK-CRIB
domain indicating that phosphorylation of Rac1 at S71 does not significantly affect GTP
binding function, but instead modulates its downstream signaling by inhibiting its
interaction with some effectors and increasing its interaction with others (Schwarz et al.,
2012). Thus, we wanted to investigate if Rac1 GTP-binding activity is modulated by
Np63. To this end, we silenced Np63 in A431 cells and measured the level of
endogenous GTP-bound (active) Rac1 by pulling down active Rac1 with purified p21activated protein kinase protein binding domain (PAK-PBD). Immunoblotting was
performed to analyze the whole cell lysates and lysates immunoprecipitated with the GSTtagged PAK-PBD. Knockdown of Np63 significantly increased the levels of pRac1 in
the whole cell lysates and total Rac1 showed no change (Figure 13, compare lanes 1 and
3). GST pull down of GTP-bound total Rac1 showed that the Np63 knockdown
significantly increased the level of GTP-Rac1 (Figure 13, lane 4). pRac1 S71 was also
detected in the immuneprecipitated material and it was also significantly increased with
the knockdown of Np63. The activity of Rac1 can also be assessed by measuring the
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Figure 13: Np63negatively regulates GTP-binding activity of Rac1. A431 cells
were transfected with non silencing control siRNA (NSC) or siRNA specific to p63.
Whole cell lysates were subjected to pull down using PAK-PBD beads which
specifically bound only GTP-bound active Rac1. Immunoblot analysis was performed
with the indicated antibodies. The amount of Rac1 visualized by immunoblot represents
the amount of GTP-bound Rac1. Immunoblot for the downstream effector pPAK1 was
included as an additional readout of Rac1 activity.
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Phosphorylation of its target effector protein PAK1. We probed for pPAK1 at Threonine
423. Knockdown of Np63 significantly increased the phosphorylation of PAK1 at T423
suggesting that increased active Rac1 levels in sip63 cells led to increased pPAK1 levels.
Our results showed that the knockdown of Np63 increased GTP-Rac1 levels as observed
early (Figures 9). Moreover, pRac1 S71 was also detectable in the activation assay
indicating that pRac1 S71 does not affect the binding of Rac1 to its effector PAK1.
G. Overexpression of Np63 decreases Rac1 localization to the plasma
membrane and induces its nuclear localization
Rac1 subcellular localization plays critical role in its function. Rac1 is associated with
the plasma membrane when it is GTP-bound and localized to the cytoplasm with RhoGDI
in its inactive state, GDP bound. However, the effect of Rac1 phosphorylation on its
localization is not well investigated. Having demonstrated that Np63 decreases pRac1
S71 and GTP-Rac1, we wanted to study the effect of Np63 on Rac1 localization. We
overexpressed GFP-Rac1 WT, GFP-Rac1 S71A, GFP-Rac1 T17N and GFP-Rac1 Q61L
(Table 4) in H1299 cells by transient transfection. GFP-Rac1 WT or mutants were
transfected alone or in conjunction with Np63 and the localization of was assessed by
immunofluorescence microscopy through measuring the intrinsic fluorescence of GFP
without the need for an anti-Rac1 antibody. We first overexpressed Np63alone as
positive control for p63 overexpression.Np63was robustly overexpressed in the
nucleus (Figure 14A). Rac1 WT was mainly localized to the plasma membrane when it
was transfected alone (Figure 14B and Figure 15) (representative images shown).
Np63overexpression decreases Rac1 WT localization to plasma membrane and targets
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it to the nucleus (Figure 14B and Figure 15). Overexpressing Rac1 S71A mutant (Table
4) decreased the localization of Rac1 to plasma membrane (48/100) in comparison to the
wild-type Rac1 (80/100), Moreover, localization of Rac1 S71A mutant to nucleus was
higher than observed with Wild type Rac1 (16/100 for Rac1S71A and 5/100 for Rac1 WT)
when expressed alone (Figure 14C and Figure 15). Consistent with wild type Rac1, cooverexpression of Np63 with Rac1 S71A also decreased Rac1 localization to the plasma
membrane and induced its nuclear localization (Figure 14C and Figure 15). Dominant
negative Rac1 T17N and the constitutively active Rac1 Q61L (Table 4) were used as
negative and positive controls for Rac1 activity, respectively. Rac1 T17N was primarily
localized either to plasma membrane (33/100) or nucleus (22/100) or in some cases
distributed over cells (Figure 14E and Figure 15). Co-expression of Np63 led to a
decrease in Rac1T17N localization to plasma membrane (19/100) and a modest increase
its localization to nucleus (43/100) (Figure 14D and Figure 15). Interestingly,
constitutively active Rac1 Q61L mutant showed increased localization to both the plasma
membrane and nucleus and in many cases was localized to both plasma membrane and
nucleus simultaneously (plasma membrane= 43/100, nucleus= 3/100 to and plasma
membrane and nucleus= 46/100). Furthermore, co-overexpression of Np63 did not
affect Rac1 Q61L localization (Figure 14E and Figure 15). These results suggest that
Np63 inhibits the activity of Rac1 as it decreases its localization to the plasma
membrane and targets it to nucleus.
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Table 4: Rac1 mutants used to study the subcellular localization of Rac1.
Rac1 mutants
Position

Wild
Type

Mutant

Description

71

S

A

Phospho-deficient at S71

17

T

N

Constitutively active (CA)
(GTP-bound)

61

Q

L

Dominant negative (DN) (GDPbound)
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Figure 14: Overexpression of Np63 decreases Rac1 localization to the plasma
membrane and induces its nuclear localization. H1299 cells were transfected with
Np63alone, Rac1 WT alone, Rac1 S71A alone, Rac1 T17N alone, Rac1 Q61L alone
or along with Np63as indicated in the panels above. The localization ofRac1 WT
or mutants was examined by fluorescence microscopy following immunostaining for
p63.
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Figure 15: Overexpression of Np63 decreases Rac1 localization to the plasma
membrane and induces its nuclear localization. Quantification of the
immunofluorescence analysis for Figure 14. Rac1 subcellular localization was
quantified by imaging at least 100 cells per condition with the same exposure
parameters. The localization of Rac1 in plasma membrane, cytoplasm or nucleus was
determined manually by evaluating each single cell. Cells were grouped into four
categories based on Rac1 localization: (Red) cells that have Rac1 mainly localized to
plasma membrane, (Orange) cells that have Rac1 mainly localized to nucleus, (Yellow)
cells that have Rac1 localized to both nucleus and cell membrane, and (Green) cells that
have Rac1 distributed over cells without main localization to either plasma membrane
or nucleus.
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H. miR320a mimic rescues the effect of Np63 silencing on invasion
Np63 is known to inhibit cell invasion by negatively regulating genes involved
in EMT (Bergholz et al., 2014; Danilov et al., 2011; Finlan & Hupp, 2007; Kommagani et
al., 2009). miR-320a was also shown to inhibit cell invasion through targeting Rac1 (Zhao
et al., 2014). In our results, we confirmed that miR-320a is positively regulated by Np63.
In addition, Np63 negatively regulates Rac1 activity and this regulation is mediated by
miR-320a. Thus, we hypothesized that Np63 may inhibit invasion through targeting
Rac1 activity via miR-320a. To this end, we transfected HaCaT cells with control mimic
or miR-320a mimic along in presence or absence of Np63 silencing and assessed cell
invasion using a transwell invasion assay. Knockdown of Np63 dramatically increased
the number of invading cells (Figure 15), consistent with the expected role of p63 and our
hypothesis. Overexpression of the miR-320a mimic in sip63 cells significantly decreased
the number of invading cells although Np63 was knocked down (Figure 15). This
experiment was repeated in A431 cells, a more invasive cell line, and same results were
obtained (Figure 16). We concluded that the increase in invasion observed upon Np63
knockdown is reversed by miR-320a mimic, potentially through targeting Rac1 activity.

54

*

*

Figure 16: Overexpression of a miR-320a mimic counters the effect of Np63
knockdown on invasion in HaCaT cells. HaCaT cells were transfected with either
non-silencing control (NSC) or sip63 in conjunction with a negative control mimic or
miR-320a mimic for two rounds of transfections. 24 hours after the second of
transfection, 8.0x104 cells were subjected to Matrigel-based invasion assay (A) and the
number of invading cells was quantitated after 21 hours (B). The y-axis represents the
number of cells invaded.
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Figure 17: Overexpression of a miR-320a mimic counters the effect of Np63
knockdown on invasion in A431 cells. A431 cells were transfected with either nonsilencing control (NSC) or sip63 in conjunction with a negative control mimic or miR320a mimic for two rounds of transfections. 24 hours after the second of transfection,
8.0x104 cells were subjected to Matrigel-based invasion assay (A) and the number of
invading cells was quantitated after 21 hours (B). The y-axis represents the number of
cells invaded.
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IV.

Discussion

Cancer invasion has remained a focus of research for many years. Invasion is the
main phenomena of tumor progression. EMT, a process in which epithelial cells lose their
characteristics and gain a mesenchymal-like phenotype, is a fundamental process in
embryonic development and during wound healing. In a carcinogenic context, EMT is
upregulated which allows cancer cells to lose their cell-cell adhesion and gain migratory
and invasive properties. Np63 is the most abundantly expressed isoform of p63 and
considered the master regulator of epithelial differentiation (Mills et al., 1999; Yang et al.,
1998). It was previously shown that Np63 suppresses cell invasion through
downregulating genes involved in EMT, however, the detailed molecular regulation of
Np63 in EMT is not fully understood (Chu et al., 2013; Tran et al., 2013; Tucci et al.,
2012). Np63 has been shown to regulate several miRNAs many of them play a role in
EMT. Thus, small RNA sequencing study was performed previously in our laboratory to
investigate the regulation of global miRNAs by Np63.
miR-320a, a tumor suppressive miRNA that is downregulated in many metastatic
cancers, was shown in our RNA-Sequencing data set to be positively regulated by Np63
(L. Sun et al., 2015; J. Yu et al., 2016; Zhang et al., 2012; Zhao et al., 2014). We confirmed
the regulation of miR-320a by Np63 through performing RT-PCR validating the small
RNA sequencing results. Here, we examined the effect of Np63 loss or gain on one of
miR-320a targets, Rac1, shown to play a critical role in cell motility. We found a novel
mechanism by which Np63 can regulate the activity of Rac1. Np63 suppresses Rac1
phosphorylation through upregulating miR-320a levels. We also showed that the negative
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regulation of pRac1 S71 by Np63 correlates with Rac-1-GTP-levels potentially through
miR-320a. This is the first study which demonstrates a mechanistic link between p63 and
Rho small GTPase family.
Rac1 belongs to the Rho family and plays a fundamental role in cellular
proliferation, adhesion, migration and gene transcription (Hartman & Spudich, 2012). The
role of Rac1 in the acquisition of invasive and metastatic phenotypes and thus cancer
progression has been well known. In the present study, we first sought to examine the direct
regulation of Rac1 by miR-320a since it was previously shown that miR-320a directly
binds to the 3’-UTR of Rac1 and reduces its expression (Zhao et al., 2014). Although we
saw a modest increase in Rac1 transcript levels upon Np63 knockdown, we did not
observe any change in total Rac1 protein levels. These results were further confirmed by
Np63 overexpression in two cell lines, SW480 and H1299 which are null for Np63
and showed no change in Rac1 transcripts or protein levels. In line with our results, the
study by Zhao et al (2014) also showed no change in Rac1 transcripts with the modulation
of miR-320a levels. Although they did see a change in total protein levels of Rac1 when
miR-320a was overexpressed, we argue here this change could be in phosphorylated Rac1
but not total Rac1 protein levels since the antibody they used detects both total Rac1 as
well as pRac1 (as shown in Figure 8).
Rho small GTPases share high homology thus it is likely that regulation of one
member of Rho family is also observed with other Rho family members. Protein
phosphorylation is thought to negatively affect RhoA and CDC42 activities, however, this
is not totally true in the context of Rac1 activity (Forget et al., 2002). In this study we focus
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on studying the only available phospho Rac1-S71 antibody which detects the
phosphorylated Rac1. We found that Rac1 phosphorylation is greatly inhibited by
Np63This pattern of regulation was observed in every experiment we have done in all
cell lines except in H1299 cells where we do not see phosphorylation of Rac1. This
suggests that the effector molecular that modulates Rac1 phosphorylation and is a target
for miR-320a is missing in H1299 cells.
One essential tool for investigating Rac1 phosphorylation is using a
phosphospecific antibody. Until recently, there was no antibody available that could detect
the phosphorylation of Rac1 at S71. Thus, previous studies that investigated the
phosphorylation of Rac1 used antibodies that could not distinguish between pRac1 and
pCdc42 S71 and were therefore limited its use in cells lacking Rac1 gene (Kwon et al.,
2000; Schoentaube et al., 2009; Schwarz et al., 2012). In the present study we used two
Rac1 antibodies that can recognize the phosphorylated form of Rac1. We confirmed the
specificity of the anti-phospho-Rac1 (S71) antibody by knockdown of Rac1 and
Np63and monitor the change in total and pRac1 levels.
Rac1 phosphorylation is poorly understood and there are contradicting reports
regarding whether phosphorylation of Rac1 at S71 affects its activity. For example, one
study showed that phosphorylation of Rac1 at S71 by Akt kinase decreases Rac-1 GTP
levels and hence its activity (Kwon et al., 2000). In contrast, another study showed that
pRac1 still binds to PAK-PBD in pull down assay indicative of active Rac1-GTP
(Schoentaube et al., 2009). Our results in this study were was consistent with the latter
study wherein we found that Np63 knockdown led to a dramatic increase in both pRac1
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S71 Rac1 GTP levels. Moreover, our observations confirmed that pPAK1 levels were
increased upon Np63 knockdown, a downstream effector of active Rac1. A recent study
showed that Rac1 phosphorylation leads to a decrease in Rac1 binding to specific effectors,
such as PAK1, and a shift in specificity toward other effectors without affecting its activity
(Schwarz et al., 2012). This could be interpreted as the reduction in the interaction between
Rac1 and PAK1 due to Rac1 phosphorylation may lead to a decrease in the cell invasion
since PAK1 is one of major mediators for Rac1 activity in cell migration and invasion. In
contrast, the increase we see in pPAK1 upon knockdown of Np63 is more likely
through upregulating Rac1 activity which means the phosphorylation of Rac1 at S71 does
not affect its binding to PAK1 in our experiments.
Based on our results it is likely that upregulation of miR-320a by Np63leads to
inhibition of a kinase upstream of Rac that is a target for miR-320a and can phosphorylate
Rac1 at S71. We exclude Akt-mediated phosphorylation in our study since our laboratory
previously showed that Np63 positively regulates Akt kinase (Leonard et al., 2011). In
silico analysis led to the identification of a number of putative kinases associated with Rac1
activity and are likely to be targets of miR-320a. However none of those have been shown
to phosphorylate Rac1. Further studies are therefore essential to determine which of the
upstream effector(s) of Rac1 mediate its phosphorylation.
Targeting Rac1 to different subcellular compartments is an important mechanism
to regulate Rac1 activity. Our study clearly demonstrated that Np63 targets Rac1 to the
nucleus. We showed that the overexpression of Np63 decreases the localization of Rac1
to the plasma membrane and induces its nuclear localization. It was previously shown that
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Rac1 accumulates in nucleus during G2 phase and induces cell division (Michaelson et al.,
2008). Moreover, Rac1 is shown to affect the transcription machinery by directly binding
to STAT3 which plays significant roles in upregulating cell proliferation (Simon et al.,
2000). Thus, targeting Rac1 to nucleus by Np63 may upregulate cell proliferation which
is known oncogenic role of Np63. Moreover, the decrease in GTP-Rac1 levels in cells
co-transfected with Np63could be as a result of Rac1 degradation in nucleus. It was
previously shown that GTP-Rac1, but not GDP-Rac1, is subjected to proteasomal
degradation in nucleus (Lanning et al., 2004). Moreover, we observed decreased plasma
membrane localization of Rac1 S71A mutant when compared to WT Rac1. This mutation
also did not increase Rac1 localization to nucleus. These results highlight the importance
of Rac1S71 phosphorylation in both the stability of Rac1 GTP activity to the plasma
membrane and the kinase that phosphorylates it is a plasma membrane kinase although this
remains to be experimentally validated. It is likely that when Rac1 activated through
binding to GTP is localized to the plasma membrane and interacts with a plasma membrane
kinases that phosphorylates it back and stabilizes its binding to plasma membrane. We also
found that the overexpression of Np63 also targets Rac1 S71A to nucleus. The
mechanism by which Np63 affects Rac1 nuclear localization is unclear and could be a
third mechanism by which Np63 can regulate Rac1 activity.
The main goal of this study is to elucidate the mechanism by which Np63 can
inhibit cell invasion. We hypothesized that Np63 inhibits cell invasion though targeting
Rac1 activity via miR-320a. Our study demonstrated that increased invasion observed upon
Np63 knockdown can be reversed by miR-320a mimic Cell invasion was significantly
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reduced after knockdown of Np63 and overexpressing miR-320a. This notion is
supported by previous data demonstrating that miR-320a greatly suppresses cell invasion
through targeting Rac1.
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V.

Conclusion

Np63 and Rac1 play central roles in cancer through modulation of cell invasion.
The work presented in this dissertation elucidates one arm by which Np63functions to
inhibit cell invasion as shown in our model (Figure 17). We showed that
Np63positively

regulatesmiR-320a

levels.

Furthermore,

we

showed

that

Np63downregulates Rac1 activity leading to inhibition in cell invasion.
Np63significantly inhibits Rac1 phosphorylation at S71 and this regulation occurs
through miR-320a (Figure 17). Further experiments are needed to identify the miR-320a
target that modulates Rac1 phosphorylation. GTP-Rac1 level is also inhibited by
Np63Figure 17). The mechanism by which Np63regulates GTP-Rac1 levels is not
fully revealed. Np63 may indirectly regulates GTP-Rac1 through either downregulating
a GEF or upregulating a GAP that induces or inhibits Rac1 GTP activity, respectively. We
further showed that the activity of PAK1 is negatively affected by Np63emphasizing
the tight and effective regulation of Rac1 by Np63Moreover, we found that
Np63reduces Rac1 localization to plasma membrane while promoting its nuclear
localization. These findings are consistent with the negative regulation of GTP-Rac1 levels
by Np63since GTP-Rac1 is bound to plasma membrane.
The interplay between Np63and Rac1 will not only allow us to understand the
anti-invasive role of Np63but may also explain some of other known biological roles
of Np63. In addition, Rho small GTPases works in signaling network to regulate
cytoskeleton rearrangement and subsequently cell motility (Sadok & Marshall, 2014). The
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regulation of one member may easily impact the regulation of other members. Thus, the
presented study strongly links Np63to regulation of Rho small GTPases.
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1

?

2

Figure 18: Np63 inhibits Rac1 activity through upregulating miR-320a. Np63 upregulates the
levels of miR-320a which targets a kinase that phosphorylates Rac1 (1). GTP-Rac1 is also regulated by
Np63 through targeting a GEF or GAP that works upstream of Rac1 (2).
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